Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874737 | 0.84 | ADORA2A (0.56) | PNPDPP4ADORA2AADORA2BPDE4A | |
| SCHEMBL28071828 | 0.84 | PNP (0.45) | PNPDPP4ADORA2AADORA2BPDPK1 | |
| SCHEMBL5048181 | 0.84 | PNP (0.45) | PNPCDK2DPP4ADORA2AADORA2B | |
| SCHEMBL669007 | 0.82 | ADORA2B (0.61) | PNPCDK2DPP4ADORA2AADORA2B | |
| SCHEMBL3671339 | 0.82 | DPP4 (0.44) | PNPDPP4ADORA2AADORA2BPDPK1 | |
| SCHEMBL667797 | 0.82 | PDE4A (0.60) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL27842808 | 0.82 | PDE4A (0.53) | PNPDPP4ADORA2AADORA2BPDPK1 | |
| SCHEMBL2343362 | 0.81 | ADORA2A (0.44) | PNPCDK2DPP4ADORA2AADORA2B | |
| SCHEMBL5504400 | 0.81 | ADORA2A (0.59) | PNPCDK2DPP4ADORA2AADORA2B | |
| SCHEMBL3428513 | 0.81 | ADORA2B (0.56) | PNPCDK2DPP4ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509603-A1 | NEW APTAMERS AGAINST EPHA2 (EPHRIN TYPE-A RECEPTOR 2) | Aptadel Therapeutics SL. (ES) | 2025-02-19 | — | — | EP | disclosed |
| US-11963842-B2 | Appliances for intraoral delivery of agents | ALIGN TECHNOLOGY, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11939365-B2 | T cell receptors recognizing mutated P53 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-03-26 | — | — | US | disclosed |
| US-11859251-B1 | Identifaction of cancer biomarkers by alignment of nucleic acid sequences | CHRONIX BIOMEDICAL (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230018058-A1 | Appliances for intraoral delivery of agents | ALIGN TECHNOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-113801878-A | Identifying heat limiting markers and heat limiting mimetics | NSE产品公司 | 2021-12-17 | — | — | CN | disclosed |
| US-10913948-B2 | RNA interference in dermal and fibrotic indications | PHIO PHARMACEUTICALS CORP. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200277352-A1 | T CELL RECEPTORS RECOGNIZING MUTATED P53 | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-09-03 | — | — | US | disclosed |
| US-10450372-B2 | Anti-thyroglobulin T cell receptors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180371464-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2018-12-27 | — | — | US | disclosed |
| US-20030022211-A1 | G-protein coupled receptor and uses therefor | WYETH | 2003-01-30 | — | — | US | disclosed |
| US-20030022813-A1 | Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20030022812-A1 | Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2003-01-30 | — | — | US | disclosed |
| WO-2002101005-A2 | A G-PROTEIN COUPLED RECEPTOR AND USES THEREFOR | WYETH (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002092000-A2 | HBM VARIANTS THAT MODULATE BONE MASS AND LIPID LEVELS | GENOME THERAPEUTICS CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002089832-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING TH1 AND TH2 CELL RELATED DISEASES BY MODULATING THE TH1/TH2 RATIO. | Alk-Abelló A/S (DK) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090499-A2 | ss-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002079401-A2 | NOVEL RGS9 PROTEIN BINDING INTERACTIONS AND METHODS OF USE THEREOF | WYETH (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020128215-A1 | Polymorphisms of the NAT-2 gene which can be involved in drug metabolism and various disorders; pharmacogenetics | GENOME THERAPEUTICS CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020065224-A1 | Caveolin-1 gene and polypeptide encoded thereby and methods of use thereof | UNIVERSITY OF LAUSANNE (CH) | 2002-05-30 | — | — | US | disclosed |